Press release
SACHS 3482083150 LuK 143028820 430MM SAAB SCANIA CLUTCH COVER
Unmatched Performance for Heavy-Duty Vehicles
Designed for SAAB and SCANIA applications, this clutch cover is a perfect fit for vehicles requiring superior durability and strength. The 430MM diameter ensures compatibility with a wide range of heavy-duty trucks and buses, offering consistent performance under challenging driving conditions.
Why Choose the SACHS and LuK Clutch Cover?
* Exceptional Build Quality Manufactured using high-grade materials, the clutch cover is resistant to wear and tear, providing a long service life even in demanding environments.
* OE Standard Assurance With OE numbers 3482083150 (SACHS) and 143028820 (LuK), this clutch cover meets or exceeds original equipment specifications, ensuring seamless integration into your vehicle's existing system.
* Enhanced Driving Safety By delivering smooth and reliable power transmission, the clutch cover contributes to better vehicle control and driver safety, especially during long hauls or under heavy loads.
Applications and Compatibility
This clutch cover is specifically engineered for SAAB and SCANIA heavy-duty vehicles. Before purchasing, confirm your vehicle's compatibility using the OE numbers: 3482083150 or 143028820.
Why Buy from Terbon Auto Parts?
At Yancheng Terbon Auto Parts Co., Ltd., we are committed to providing top-quality auto parts for the automotive industry. Our products undergo rigorous testing to ensure they meet the highest performance standards. Whether you're looking for brake pads, clutch kits, or other essential components, you can count on us for reliable solutions.
Order Your SACHS 3482083150 LuK 143028820 Clutch Cover Today!
Don't compromise on safety or performance. Click here [https://www.terbonparts.com/sachs-3482083150-luk-143028820-430mm-saab-scania-clutch-cover-product/] to learn more and place your order today.
Media Contact
Company Name: Yancheng Terbon Auto Parts Co., Limited
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=sachs-3482083150-luk-143028820-430mm-saab-scania-clutch-cover]
Country: China
Website: https://www.terbonparts.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release SACHS 3482083150 LuK 143028820 430MM SAAB SCANIA CLUTCH COVER here
News-ID: 3790373 • Views: …
More Releases from ABNewswire
SEO Agency Dubai: How Data-Driven Search Strategies Are Shaping Digital Growth
Explore how a data-driven SEO agency in Dubai helps businesses grow online through advanced search strategies, analytics, and performance-based SEO. Visit us today!
Dubai's digital economy is moving fast, and visibility has become a decisive factor in growth. Businesses competing in saturated markets can no longer rely solely on paid ads. They need organic authority, credibility, and long-term discoverability. This is where an SEO agency Dubai [https://www.google.com/search?SEO+agency+Dubai&kgmid=/g/11v3f6wqbl] businesses trust becomes essential,…
The Life and Loves of an Artist Illuminates the Remarkable Journey Behind a Life …
Authors Paul and Gail King present The Life and Loves of an Artist. This sweeping biographical narrative traces the extraordinary story of a family whose lives were intertwined with art, resilience, and history.
Rooted in meticulous research and personal reflection, the book offers a moving portrait of two generations shaped by both hardship and inspiration.
Purpose of the Book
What started as an attempt to remember family memories became a vivid journey of…
Alzheimer's Disease Market in the 7MM is projected to reach USD 34 Billion by 20 …
Key players operating in the Alzheimer's disease market include Eisai, Biogen, Changchun Huayang High-tech Co. Ltd., Hoffmann-La Roche, vTv Therapeutics, AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Prilenia Therapeutics, Denali Therapeutics Inc., Stemedica Cell Technologies, Inc., along with several other emerging and established companies.
The Alzheimer's disease market was valued at approximately USD 3,610 million…
Glaucoma Market Forecast 2034: USD 4,073 Million Market Size, 30+ Companies, and …
Major Glaucoma players include Allergan (AbbVie), Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., Alcon, D. Western Therapeutics Institute (DWTI), Kowa Ltd., Senju Pharmaceuticals, Otsuka Pharmaceuticals, Bausch and Lomb, Novartis, Merck & Co., Aerie Pharmaceuticals, Nicox Ophthalmics, Sylentis, Envisia Therapeutics, Ocuphire Pharma, TearClear, Peregrine Ophthalmic, and others.
The Glaucoma Market across the seven major markets (7MM) - the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom,…
More Releases for SACHS
Mississippi Businesswoman Accepted into Goldman Sachs Cohort Program
Executive Coach Candie L. Simmons has been selected to join the prestigious Goldman Sachs One Million Black Women cohort program, a significant initiative to drive economic opportunity for Black women. Goldman Sachs One Million Black Women is a $10 billion investment commitment with $100 million in philanthropic capital to drive economic opportunity for one million Black women by 2030. One Million Black Women is a first-of-its-kind comprehensive investment focused on…
Tay Sachs Disease Market Size, Report and Forecast 2024-2032
The Tay Sachs disease market size was valued at USD 2.3 billion in 2023, driven by the increasing investment in the domain across the major markets. The market size is anticipated to grow at a CAGR of 5.6% during the forecast period of 2024-2032 to achieve a value of USD 3.83 billion by 2032.
Tay Sachs Disease: Introduction
Tay-Sachs disease is a rare, inherited neurodegenerative disorder. It's caused by the absence of…
Goldman Sachs Wealth Management Report- Competitor Profile
This competitor profile provides a comprehensive analysis of Goldman Sachs' private banking and wealth management operations. It offers insight into the company's strategy and financial performance, including key data on assets under management. Customer targeting, service proposition, product innovation, and marketing activities are also covered.
Single User License: US $ 1295
Purchase this Report @ https://www.marketreportsonline.com/contacts/purchase.php?name=836340
Goldman Sachs is one of the leading financial services companies globally, with a presence in 29 locations.…
Tay-Sachs Disease Therapeutics- Pipeline Analysis 2018, Clinical Trials & Result …
Tay-Sachs is a lysosomal storage disorder caused by the deficiency of vital enzymes called beta-hexosaminidase A (Hex-A). The role of Hex-A is to degrade a fatty substance or lipid called GM-2 ganglioside. In the absence of the Hex-A enzymes, GM-2 accumulates abnormally in cells, especially in the nerve cells or neurons, of the brain.
Download the sample report @ https://www.pharmaproff.com/request-sample/1107
In children, the destructive process begins in the fetus early in pregnancy.…
Volunteers from Goldman Sachs Visit Treloars Disabled School
Nineteen workers from the London office of the global organisation visited the College on 1st July to transform the entrance to the site into a feast of greenery.
Project Leader, Nic Hobbs, admitted spending the day gardening was a far cry from his usual tasks as a Project Manager in the Technology Division at Goldman Sachs.
He explained: "Goldman Sachs employees spend a day every year doing some sort of community based…
AAA, Goldman Sachs Upgrade Fibria Celulose to BUY Rating
Analysts have issued a research note to investors today, 4 April 2011, announcing that they have upgraded shares in Fibria Celulose S.A. (NYSE: FBR) to "buy".
Boston, Mass, April 06, 2011 -- Analysts have issued a research note to investors today, 4 April 2011, announcing that they have upgraded shares in Fibria Celulose S.A. (NYSE: FBR) to "buy".
Goldman Sachs had previously upgraded the eucalyptus firm’s stocks to "neutral" from "underweight" earlier…
